[EN] 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR [FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 3-(1H-PYRAZOL-4-YL)PYRIDINE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE
[EN] IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QUE MODULATEURS D'IL-17
申请人:UCB BIOPHARMA SRL
公开号:WO2020261141A1
公开(公告)日:2020-12-30
A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-α]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor
申请人:Acton, III John J.
公开号:US11149036B2
公开(公告)日:2021-10-19
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
申请人:Merck Sharp & Dohme Corp.
公开号:EP3644992A1
公开(公告)日:2020-05-06
IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS
申请人:UCB Biopharma SRL
公开号:EP3990459A1
公开(公告)日:2022-05-04
Imidazopyridine Derivatives as IL-17 Modulators
申请人:UCB Biopharma SRL
公开号:US20220227764A1
公开(公告)日:2022-07-21
A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-a]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.